TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02930447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous glue
Description: Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
Study: NCT05910398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrotinib
Description: an irreversible anti-HER2 tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: an irreversible anti-HER2 tyrosine kinase inhibitor
Study: NCT04995159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single anti-platelet therapy
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual anti-platelet therapy
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
Study: NCT06140641

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Bifidobacterium Longum BL21 or placebo for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Bifidobacterium Longum BL21 or placebo for 8 weeks.
Study: NCT05588219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP synchronous with radiotherapy
Description: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
Study: NCT06370715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro-aabc
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT04614051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-DC
Description: Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
Study: NCT04781920

Intervention type: OTHER
Intervention: datas collection
Description: data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
Study: NCT06114901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SleepFix
Description: SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep health Education modules
Description: Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
Study: NCT06307860

Intervention type: DEVICE
Intervention: pulsed field ablation
Description: Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
Study: NCT06280586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: * bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró.
Study: NCT04967495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE combined with lenvatinib and iodion-125 seeds brachytherapy
Description: TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE combined with lenvatinib
Description: TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Study: NCT05383820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Study: NCT04791384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: taken orally
Study: NCT05988814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX treatment
Description: Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression
Study: NCT05464095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
Study: NCT04938648

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led deprescribing intervention
Description: 1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Description: 1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
Study: NCT06486831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squeeze the stress ball.
Description: The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
Study: NCT05213169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Hydrochloride 5mg/ml
Description: Product administered using an external continuous subcutaneous infusion pump.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 9mg/ml
Description: Product administered using an external continuous subcutaneous infusion pump.
Study: NCT05819892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)
Study: NCT06122584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007
Description: Diagnostic radiopharmaceutical for PET scan
Study: NCT04788264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive Fitbit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Receive Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Receive consultation from a physical therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: Receive consultation from a physical therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend exercise training sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend sessions with a behavioral therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study: NCT05528952

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
Study: NCT06479785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Program for machine workers
Description: A detailed Educational Intervention Program for marble factory workers working on Machines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Program for manual workers
Description: A detailed Educational Intervention Program for marble factory workers working manually.
Study: NCT05482243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
Study: NCT05249166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALINFA
Description: Comparing the usual recommendations with the healthy diet designed and developed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group
Study: NCT05438108

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab
Description: SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
Study: NCT05180825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
Study: NCT04921098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser Cyclophotocoagulation
Description: A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
Study: NCT05605145

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR was used to detect pneumocystis in respiratory specimens
Description: Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.
Study: NCT05420363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different walking surfaces
Description: different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional gait training over hard surface only
Description: The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
Study: NCT05541315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88260237
Description: JNJ-88260237 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study: NCT05877677

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygonatum kingianum extract drink
Description: consume 1 bottle per day
Study: NCT06632600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXE408
Description: LXE408 administered by oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXE408
Description: LXE408 administered by oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by oral route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by oral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Benznidazole administered by oral route (administered as standard of care)
Study: NCT05349513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESSME questionnaire
Description: The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
Study: NCT06742645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Description: Brief Motivational Interviewing (BMI), the object of the training and of the present research study, is an interview methodology that includes the intervention on the motivation to change of subjects with risky behaviors for their health, in order to obtain changes in their lifestyle and maintain correct behaviors for health over time (1). The BMI is mainly based on the Transtheoretical Model of Change by Di Clemente CC. and Prochaska JO (2).~In particular, the BMI has been defined by its creators, Miller and Rollnick, as a collaborative style of conversation aimed at strengthening motivation and commitment to change (3), both through defined attitudes, strategies and techniques, and through the exploration of ambivalence or internal fracture, which together with availability and a sense of self-efficacy (4) provides a framework of personal motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC) - The health workers of the Navile Community House carry out the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire
Study: NCT04626050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Music
Description: Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Writing
Description: Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Psychotherapy including imaginal exposure for PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning